×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Ascites Market

ID: MRFR/MED/13959-HCR
100 Pages
Rahul Gotadki
October 2025

US Ascites Market Research Report By Type (Transudative Ascites, Exudate Ascites), By Diagnosis (Ultrasound, CT Scan, Laparoscopy, Angiography), By Treatment (Surgeries) and By End User (Hospitals & Clinics, Ambulatory Surgical Center, Diagnostic Centers) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Ascites Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

US Ascites Market Summary

As per MRFR analysis, the US ascites market Size was estimated at 336.4 USD Million in 2024. The US ascites market is projected to grow from 361.63 USD Million in 2025 to 745.25 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 7.5% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The US ascites market is experiencing growth driven by increasing liver disease prevalence and advancements in treatment technologies.

  • The rising incidence of liver diseases is significantly influencing the demand for ascites management solutions.
  • Advancements in diagnostic technologies are enhancing early detection and treatment options for ascites patients.
  • Increased awareness and education regarding liver health are contributing to a growing patient population seeking treatment.
  • The market is primarily driven by the growing aging population and rising healthcare expenditure, which support chronic disease management initiatives.

Market Size & Forecast

2024 Market Size 336.4 (USD Million)
2035 Market Size 745.25 (USD Million)
CAGR (2025 - 2035) 7.5%

Major Players

Bristol-Myers Squibb (US), Roche (CH), Novartis (CH), Gilead Sciences (US), Merck & Co. (US), Amgen (US), AbbVie (US), Johnson & Johnson (US)

US Ascites Market Trends

The ascites market is currently experiencing notable developments driven by various factors. The increasing prevalence of liver diseases, particularly cirrhosis and hepatitis, has led to a rise in the number of patients suffering from ascites. This condition, characterized by the accumulation of fluid in the abdominal cavity, necessitates effective management strategies. Healthcare providers are focusing on innovative treatment options, including diuretics and paracentesis, to alleviate symptoms and improve patient outcomes. Furthermore, advancements in diagnostic technologies are enhancing the ability to detect ascites at earlier stages, which may contribute to better management and treatment protocols. In addition, the ascites market is influenced by the growing awareness of the condition among healthcare professionals and patients alike. Educational initiatives and outreach programs are being implemented to inform stakeholders about the importance of early diagnosis and treatment. This heightened awareness is likely to drive demand for effective therapies and management solutions. Moreover, the ongoing research into novel therapeutic agents and clinical trials may further shape the landscape of the ascites market, potentially leading to improved treatment options and better patient care in the future.

Rising Incidence of Liver Diseases

The ascites market is witnessing an increase in cases related to liver diseases, particularly cirrhosis and hepatitis. This trend is likely to drive demand for effective management solutions, as healthcare providers seek to address the growing patient population.

Advancements in Diagnostic Technologies

Innovations in diagnostic tools are enhancing the detection of ascites, allowing for earlier intervention. This development may lead to improved patient outcomes and a shift in treatment approaches within the ascites market.

Increased Awareness and Education

There is a growing emphasis on educating healthcare professionals and patients about ascites. This trend is expected to foster a better understanding of the condition, potentially increasing the demand for effective therapies and management strategies.

US Ascites Market Drivers

Growing Aging Population

The ascites market is experiencing growth driven by the increasing aging population in the US. As individuals age, the prevalence of chronic diseases, particularly liver-related conditions, rises significantly. According to the US Census Bureau, the population aged 65 and older is projected to reach 80 million by 2040, which may lead to a higher incidence of ascites. This demographic shift suggests a potential increase in demand for treatment options and management strategies within the ascites market. Healthcare providers may need to adapt their services to cater to this growing population, thereby influencing market dynamics. Furthermore, the aging population often requires more complex healthcare solutions, which could further stimulate innovation and investment in the ascites market.

Rising Healthcare Expenditure

Healthcare expenditure in the US has been on an upward trajectory, which appears to positively impact the ascites market. The Centers for Medicare & Medicaid Services (CMS) reported that national health spending is projected to grow at an average rate of 5.4% annually, reaching approximately $6 trillion by 2027. This increase in spending may facilitate better access to advanced treatment options for ascites, including medications and surgical interventions. As healthcare budgets expand, there is a potential for increased funding for research and development in the ascites market, leading to innovative therapies and improved patient outcomes. Consequently, the financial commitment to healthcare may enhance the overall landscape of the ascites market.

Technological Innovations in Treatment

Technological advancements in treatment modalities are likely to play a crucial role in shaping the ascites market. Innovations such as minimally invasive procedures, novel drug formulations, and improved monitoring devices are emerging. For instance, the development of automated paracentesis devices may enhance the efficiency and safety of fluid removal in patients with ascites. The integration of telemedicine and digital health solutions also appears to facilitate better patient management and follow-up care. As these technologies become more prevalent, they may lead to improved patient outcomes and satisfaction, thereby driving growth in the ascites market. The ongoing research and development in this area suggest a promising future for the treatment landscape.

Regulatory Support for Innovative Therapies

Regulatory bodies in the US are increasingly supportive of innovative therapies, which may positively influence the ascites market. The Food and Drug Administration (FDA) has implemented various initiatives to expedite the approval process for new treatments, particularly those addressing unmet medical needs. This regulatory environment encourages pharmaceutical companies to invest in research and development for novel therapies targeting ascites. The potential for faster market entry of new drugs and treatment options could stimulate competition and drive advancements in the ascites market. As a result, patients may benefit from a wider array of treatment choices, ultimately enhancing the overall market landscape.

Increased Focus on Chronic Disease Management

The ascites market is likely to benefit from the growing emphasis on chronic disease management in the US healthcare system. With the rising burden of liver diseases and associated complications, healthcare providers are increasingly prioritizing comprehensive management strategies. This shift may lead to enhanced care pathways for patients with ascites, including multidisciplinary approaches that involve specialists in hepatology, nutrition, and palliative care. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) indicates that effective management of chronic liver diseases can significantly improve patient quality of life. As healthcare systems adapt to these needs, the ascites market may experience growth driven by the demand for integrated care solutions.

Market Segment Insights

By Type: Transudative Ascites (Largest) vs. Exudate Ascites (Fastest-Growing)

In the US ascites market, transudative ascites accounts for the largest share, dominating the segment due to its prevalence in conditions like cirrhosis and heart failure. This type represents a significant portion of the total ascites cases, reflecting a stable market presence that is bolstered by the chronic nature of its underlying causes. Exudate ascites, while smaller in overall volume, is gaining traction and capturing a larger market share due to increasing incidences related to malignancies and infections, pushing its demand forward. Growth trends indicate a steady rise in both segments but with differing drivers. Transudative ascites growth is primarily supported by advancements in treatment protocols and increased awareness among healthcare providers, leading to improved patient management. Conversely, exudate ascites is seeing strong growth trends attributed to rising cancer rates and innovative diagnostic techniques. This divergence creates unique opportunities for stakeholders in the US ascites market, leading to tailored strategies addressing the distinct needs of each segment.

Ascites Type: Transudative (Dominant) vs. Exudate (Emerging)

Transudative ascites holds a dominant position in the US ascites market, characterized by its occurrence in patients with chronic health problems, predominantly cirrhosis and cardiac issues. This segment benefits from a well-established treatment landscape and ongoing investment in research aimed at improving patient outcomes. In contrast, exudate ascites is emerging rapidly, driven largely by its association with various malignancies and inflammatory conditions. This shift towards an increased diagnosis of exudative cases coupled with advancements in treatment options and diagnostic procedures has positioned it for significant growth. Stakeholders must recognize the differences in market dynamics and healthcare needs between these two types to capitalize on their respective potentials.

By Diagnosis: Ultrasound (Largest) vs. CT scan (Fastest-Growing)

The US ascites market showcases a diverse range of diagnostic methods, with Ultrasound currently holding a significant portion of the market share due to its affordability, availability, and effectiveness in fluid detection in the abdominal cavity. Following closely is the CT scan, which, while having a smaller share, is rapidly gaining traction among healthcare providers due to its detailed imaging capabilities and ability to assist in diagnosing underlying conditions leading to ascites. This increase in usage is driving a shift in the overall diagnostic landscape.

Ultrasound (Dominant) vs. CT scan (Emerging)

Ultrasound stands out as the dominant diagnostic tool in this market, favored for its non-invasive nature and real-time imaging ability, making it a first-line approach for assessing ascites. In contrast, the CT scan is emerging as a vital alternative, especially where complex diagnoses are required, providing highly accurate anatomical information. This diagnostic method is becoming more prevalent due to advancements in imaging technology that enhance its effectiveness. Both modalities play crucial roles in the diagnostic pathway, with Ultrasound cementing its status as the standard and CT scans breaking ground as an essential supplementary technique.

By Treatment: Medication (Largest) vs. Paracentesis (Fastest-Growing)

In the US ascites market, the treatment segment is primarily dominated by medication, which commands a significant market share due to its widespread adoption and effectiveness. Paracentesis has emerged as a considerable alternative, particularly appealing to patients with refractory ascites. Surgery remains an essential treatment; however, it accounts for a smaller portion of the overall market. This distribution highlights the varying preferences and treatment outcomes experienced by patients based on their specific health conditions. Growth trends show that the ascites treatment segment is evolving, driven by advancements in medical technology and increased awareness of treatment options. The rising incidence of liver-related diseases is fueling demand for efficient and effective treatments. Paracentesis stands out as the fastest-growing segment, thanks to its minimally invasive nature and quicker recovery times compared to surgical interventions. Continual research and innovation will likely shape this market in the coming years, enhancing patient care and expanding treatment access.

Medication (Dominant) vs. Surgery (Emerging)

Medication plays a dominant role in the treatment landscape for ascites, primarily due to its comprehensive approach to managing symptoms related to fluid accumulation. This treatment often includes diuretics and other pharmacological agents, which provide effective management options for patients. In contrast, surgery is viewed as an emerging treatment method, particularly for patients who are candidates for more invasive procedures. While surgery may pose greater initial risks, it can offer long-term solutions for patients suffering from severe ascites. The market position of these treatments reflects a balance of efficacy and patient preference, influencing healthcare providers in their treatment approaches.

By Route of Administration: Oral (Largest) vs. Parenteral (Fastest-Growing)

In the US ascites market, the distribution of market share among the routes of administration is noteworthy. Oral administration stands as the largest segment, capturing a significant portion due to its convenience and patient compliance. Parenteral routes also play a crucial role, particularly in severe conditions requiring rapid therapeutic intervention. The other segment, while smaller, contributes to niche markets serving specific patient needs and preferences. Growth trends within this segment indicate an increasing shift towards parenteral administration, driven by technological advancements and the need for faster therapeutic effects. The emergence of innovative delivery systems is enhancing the appeal of injectable treatments, leading to an accelerated adoption rate. Meanwhile, oral administration continues to thrive, sustained by ongoing developments in formulation technologies that improve bioavailability and patient adherence.

Oral (Dominant) vs. Parenteral (Emerging)

Oral administration is characterized by its user-friendly approach, making it the dominant route in the US ascites market. Patients favor oral medications due to ease of use and the potential for self-administration. The segment benefits from continuous innovation in drug formulations, which enhances efficacy and minimizes gastrointestinal side effects. On the other hand, parenteral administration is rapidly emerging as a preferred option for many healthcare providers, especially in acute care settings. The ability to achieve immediate drug action and ensure precise dosing makes it invaluable in managing ascites. As the market evolves, both routes will likely coexist, addressing diverse patient needs while shaping the overall therapeutic landscape.

By End-users: Hospitals (Largest) vs. Specialty Clinics (Fastest-Growing)

In the US ascites market, end-user segmentation reveals a significant distribution of preference, with hospitals holding the largest market share. These institutions are equipped with advanced medical infrastructure and expertise, which makes them the primary choice for treating ascites. Specialty clinics, while not as dominant, are rapidly gaining traction, offering targeted treatments and specialized care that appeal to a particular patient demographic. The growth trends in this segment indicate a shift towards outpatient care, particularly in specialty clinics. Factors driving this trend include enhanced patient satisfaction, reduced hospital stays, and the increasing focus on personalized treatment options. As home care services evolve, patients are more open to receiving care outside traditional hospital settings, further pushing the growth of specialty clinics.

Hospitals (Dominant) vs. Specialty Clinics (Emerging)

Hospitals continue to dominate the US ascites market as they provide comprehensive services and advanced technologies, making them a critical player in patient management. Their robust infrastructure allows for the treatment of severe ascites cases, including those requiring surgical interventions. Conversely, specialty clinics are emerging as key competitors by providing focused services tailored to patients' needs. These clinics benefit from lower operational costs and faster patient turnover, enabling them to cater to a growing population interested in non-invasive procedures and outpatient care. The integration of telehealth services within specialty clinics further enhances patient outreach, making them an attractive option for managing ascites efficiently.

By Allotment Channel: Hospital Pharmacies (Largest) vs. Online Pharmacies (Fastest-Growing)

The US ascites market shows a notable distribution of market share among different allotment channels. Hospital pharmacies account for the largest share, reflecting their pivotal role in inpatient treatment and access to specialized pharmaceuticals. Retail pharmacies also maintain a significant presence, catering to outpatient needs and general medication distribution. Online pharmacies are rapidly gaining traction, driven by the shift towards digital healthcare solutions and patient convenience, which is reshaping purchasing behaviors in the market. Growth trends in this segment reveal that while hospital pharmacies remain dominant, online pharmacies are emerging as the fastest-growing channel. The increasing demand for home healthcare and the convenience of online prescription services are major drivers of this growth. Additionally, the ongoing digital transformation in healthcare facilitates a seamless online purchasing experience, attracting a broader customer base and enhancing market access for patients requiring ascites treatment.

Hospital Pharmacies (Dominant) vs. Online Pharmacies (Emerging)

Hospital pharmacies are a crucial component of the US ascites market, primarily serving patients in clinical settings. They specialize in the preparation and dispensing of medications for inpatients, ensuring access to critical therapies. Their established network facilitates efficient medication management, contributing significantly to patient outcomes. On the other hand, online pharmacies are gaining momentum as an emerging force in the market. They offer convenience and accessibility, allowing patients to order medications from home. This segment is particularly attractive to tech-savvy consumers who value the ease of online transactions and home delivery services, positioning online pharmacies as an important player in the evolving landscape of healthcare distribution.

Get more detailed insights about US Ascites Market
Request Free Sample

Key Players and Competitive Insights

The ascites market exhibits a complex competitive landscape characterized by a blend of innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Bristol-Myers Squibb (US), Gilead Sciences (US), and AbbVie (US) are actively shaping the market dynamics through their distinct operational strategies. Bristol-Myers Squibb (US) emphasizes research and development, particularly in novel therapies targeting liver diseases, which are often associated with ascites. Gilead Sciences (US) has been focusing on expanding its portfolio through strategic acquisitions, enhancing its capabilities in treating liver-related conditions. AbbVie (US), on the other hand, is leveraging its strong pipeline of immunology products to address complications arising from ascites, thereby positioning itself as a leader in this niche market. Collectively, these strategies foster a competitive environment that prioritizes innovation and patient outcomes.

The business tactics employed by these companies reflect a concerted effort to optimize operations and enhance market presence. Localizing manufacturing and optimizing supply chains are prevalent strategies aimed at reducing costs and improving efficiency. The ascites market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they drive advancements in treatment options and set industry standards.

In October 2025, Gilead Sciences (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel therapeutic agent aimed at treating ascites-related complications. This collaboration is expected to accelerate the development timeline and enhance Gilead's competitive edge in the market. The strategic importance of this partnership lies in its potential to leverage combined expertise and resources, thereby expediting the delivery of innovative solutions to patients.

In September 2025, AbbVie (US) launched a new clinical trial for a combination therapy targeting ascites in patients with advanced liver disease. This initiative underscores AbbVie's commitment to addressing unmet medical needs and highlights its proactive approach to research. The trial's outcomes could significantly influence treatment protocols and establish AbbVie as a frontrunner in the ascites therapeutic landscape.

In August 2025, Bristol-Myers Squibb (US) expanded its research facilities in the US, focusing on liver disease and ascites. This expansion is indicative of the company's long-term vision to enhance its R&D capabilities and foster innovation. By investing in state-of-the-art facilities, Bristol-Myers Squibb aims to attract top talent and accelerate the development of groundbreaking therapies, thereby reinforcing its market position.

As of November 2025, the ascites market is increasingly defined by trends such as digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and accelerating innovation. Looking ahead, competitive differentiation is likely to evolve, shifting from traditional price-based competition to a focus on technological advancements, innovative therapies, and reliable supply chains. This transition may redefine market dynamics, emphasizing the importance of agility and responsiveness in meeting patient needs.

Key Companies in the US Ascites Market market include

Industry Developments

Recent developments in the US Ascites Market have been significant, particularly regarding advancements in treatment options and company activities. In October 2023, Novartis announced increased investment in Research and Development for its innovative therapies targeting patients with ascites due to liver disease. Merck has been actively expanding its portfolio with novel compounds in clinical trials aiming at effective management of ascites-related complications. The US market has also seen an uptick in the valuation of companies like Gilead Sciences and Takeda Pharmaceuticals, attributed to robust demand for effective ascites management treatments, which is elevating overall market growth.

Mergers and acquisitions have been a focal point as well; in September 2023, Bristol-Myers Squibb completed its acquisition of an emerging biotech firm specializing in ascites management, enhancing its capabilities in this space. Baxter International and Fresenius Kabi are investing heavily in newer technologies for fluid management, expecting to improve patient outcomes. Over the past two years, the US Ascites Market has experienced notable shifts with the regulatory landscape evolving to facilitate faster approvals for innovative therapies, significantly impacting treatment paradigms for patients suffering from this condition.

Future Outlook

US Ascites Market Future Outlook

The Ascites Market is projected to grow at a 7.5% CAGR from 2024 to 2035, driven by advancements in treatment options, increasing prevalence of liver diseases, and enhanced diagnostic technologies.

New opportunities lie in:

  • Development of targeted therapies for ascites management
  • Expansion of telehealth services for patient monitoring
  • Investment in AI-driven diagnostic tools for early detection

By 2035, the ascites market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased healthcare investments.

Market Segmentation

US Ascites Market Type Outlook

  • Transudative Ascites
  • Exudate Ascites

US Ascites Market Diagnosis Outlook

  • Ultrasound
  • CT scan
  • MRI
  • Blood test
  • Laparoscopy
  • Angiography

US Ascites Market End-users Outlook

  • Hospitals
  • Specialty Clinics
  • Home Care

US Ascites Market Treatment Outlook

  • Medication
  • Paracentesis
  • Surgery

US Ascites Market Allotment Channel Outlook

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

US Ascites Market Route of Administration Outlook

  • Oral
  • Parenteral
  • Others

Report Scope

MARKET SIZE 2024 336.4(USD Million)
MARKET SIZE 2025 361.63(USD Million)
MARKET SIZE 2035 745.25(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 7.5% (2024 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Bristol-Myers Squibb (US), Roche (CH), Novartis (CH), Gilead Sciences (US), Merck & Co. (US), Amgen (US), AbbVie (US), Johnson & Johnson (US)
Segments Covered Type, Diagnosis, Treatment, Route of Administration, End-users, Allotment Channel
Key Market Opportunities Advancements in minimally invasive procedures enhance treatment options in the ascites market.
Key Market Dynamics Rising demand for innovative therapies drives competition and regulatory scrutiny in the ascites market.
Countries Covered US

Leave a Comment

FAQs

What is the projected market size of the US Ascites Market in 2024?

In 2024, the US Ascites Market is projected to be valued at 290.0 million USD.

How much is the US Ascites Market expected to grow by 2035?

By 2035, the US Ascites Market is expected to reach a value of 580.0 million USD.

What is the expected CAGR for the US Ascites Market from 2025 to 2035?

The expected CAGR for the US Ascites Market from 2025 to 2035 is 6.504 percent.

What segment of the US Ascites Market is valued at 120.0 million USD in 2024?

The Transudative Ascites segment is valued at 120.0 million USD in 2024.

What is the expected value of the Exudate Ascites segment by 2035?

The Exudate Ascites segment is expected to be valued at 340.0 million USD by 2035.

Who are the key players in the US Ascites Market?

Major players in the US Ascites Market include Novartis, Merck, BristolMyers Squibb, and Gilead Sciences.

What are the dominant applications driving the US Ascites Market?

The dominant applications in the US Ascites Market include treatments for Transudative and Exudate Ascites.

What factors are driving growth in the US Ascites Market?

Key growth drivers for the US Ascites Market include increasing prevalence of liver diseases and advancements in treatment options.

How do current global trends impact the US Ascites Market?

Current global trends may impact the US Ascites Market by influencing treatment availability and pharmaceutical innovations.

What is the forecasted growth rate for the Transudative Ascites segment from 2025 to 2035?

The Transudative Ascites segment is expected to show significant growth contributing to the overall CAGR of 6.504 percent.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓